Janux Therapeutics Inc (NASDAQ: JANX) kicked off on Monday, down -3.64% from the previous trading day, before settling in for the closing price of $46.76. Over the past 52 weeks, JANX has traded in a range of $7.79-$71.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 32.66%. While this was happening, its average annual earnings per share was recorded -7.51%. With a float of $46.79 million, this company’s outstanding shares have now reached $52.34 million.
Let’s determine the extent of company efficiency that accounts for 64 employees. In terms of profitability, gross margin is 87.98%, operating margin of -658.76%, and the pretax margin is -463.91%.
Janux Therapeutics Inc (JANX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Janux Therapeutics Inc is 19.04%, while institutional ownership is 78.43%. The most recent insider transaction that took place on Jan 07 ’25, was worth 300,004. In this transaction President and CEO of this company sold 5,000 shares at a rate of $60.00, taking the stock ownership to the 293,054 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Officer proposed sale 5,000 for $60.00, making the entire transaction worth $300,004.
Janux Therapeutics Inc (JANX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.51% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Take a look at Janux Therapeutics Inc’s (JANX) current performance indicators. Last quarter, stock had a quick ratio of 38.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 199.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -1.93 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Looking closely at Janux Therapeutics Inc (NASDAQ: JANX), its last 5-days average volume was 1.77 million, which is a jump from its year-to-date volume of 1.49 million. As of the previous 9 days, the stock’s Stochastic %D was 13.67%. Additionally, its Average True Range was 4.44.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 15.91%, which indicates a significant increase from 15.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.11% in the past 14 days, which was lower than the 87.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $54.31, while its 200-day Moving Average is $47.82. However, in the short run, Janux Therapeutics Inc’s stock first resistance to watch stands at $46.83. Second resistance stands at $48.59. The third major resistance level sits at $51.01. If the price goes on to break the first support level at $42.65, it is likely to go to the next support level at $40.23. Should the price break the second support level, the third support level stands at $38.47.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
The company with the Market Capitalisation of 2.60 billion has total of 52,482K Shares Outstanding. Its annual sales at the moment are 8,080 K in contrast with the sum of -58,290 K annual income. Company’s last quarter sales were recorded 440 K and last quarter income was -28,060 K.